- Previous Close
102.30 - Open
101.70 - Bid 102.77 x 200
- Ask 103.23 x 100
- Day's Range
99.11 - 104.88 - 52 Week Range
41.16 - 113.51 - Volume
731,212 - Avg. Volume
464,325 - Market Cap (intraday)
7.268B - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
-- - EPS (TTM)
-2.79 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
112.40
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
www.nuvalent.comRecent News: NUVL
View MorePerformance Overview: NUVL
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUVL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUVL
View MoreValuation Measures
Market Cap
7.22B
Enterprise Value
6.56B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
11.34
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.71%
Return on Equity (ttm)
-32.81%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-173.58M
Diluted EPS (ttm)
-2.79
Balance Sheet and Cash Flow
Total Cash (mrq)
657.99M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-68.64M
Research Analysis: NUVL
View MoreCompany Insights: NUVL
NUVL does not have Company Insights